Cross-neutralization of convalescent sera from patients infected with novel coronavirus to COVID-19

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300078127

Enrollment

Unknown

Registered

2023-11-29

Start date

2023-04-07

Completion date

Unknown

Last updated

2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Observation group:N/A

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) voluntarily sign an informed consent form 2) the patients with covid-19 infection in China have recovered 3) the antigen turned negative for more than 30 days

Exclusion criteria

Exclusion criteria: 1) immunocompromised 2) incomplete case data

Design outcomes

Primary

Measure	Time frame
Neutralizing antibody;	—

Countries

China

Contacts

Public ContactXiong Yufeng

Nanfang Hospital of Southern Medical University

xyuf9002@163.com+86 155 2110 5662

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026